

From: Naoko KOMEIJI **On Behalf Of** international@jpma.or.jp
Sent: Monday, March 07, 2011 2:00 AM
To: track_I_comments
Subject: Comments on "track1 "

Dear Commissioner,

We appreciate the opportunity to present our views on the proposed "Changes To Implement the Prioritized Examination Track (Track 1) of the Enhanced Examination Timing Control Procedures", published in the Federal Register on February 4, 2011.

Please see the attached.
If you have any questions, please contact to international@jpma.or.jp

Yours faithfully,

Naoko Komeiji on behalf of Yuji Watanabe,
Head of Intellectual Property Committee
The Japan Pharmaceutical Manufacturers Association (JPMA)
3-4-1 Nihonbashi-honcho, Chuo-ku, Tokyo 103-0023
TEL: +81-3-3241-0326 FAX: +81-3-3242-1767

From: Naoko KOMEIJI [mailto:komeiji@jpma.or.jp] **On Behalf Of** international@jpma.or.jp
Sent: Thursday, August 19, 2010 5:03 PM
To: 3trackscomments@uspto.gov
Subject: Comments on "Enhanced Examination Timing Control Initiative"

Dear Commissioner,

We, the Japan Pharmaceutical Manufacturers Association (JPMA) appreciates the opportunity to present our views on the proposed "Enhanced Examination Timing Control Initiative", published in the Federal Register on June 4, 2010.

Please see the attached file.
If you have any questions, please contact to international@jpma.or.jp

Yours faithfully

Naoko Komeiji
Japan Pharmaceutical Manufacturers Association
3-4-1 Nihonbashi-honcho, Chuo-ku, Tokyo 103-0023
TEL: +81-3-3241-0326 FAX: +81-3-3242-1767

March 7, 2011

Commissioner for Patents
U.S. Patent and Trademark Office
United States Department of Commerce
P.O. Box 1450
Alexandria, VA 22313-1450
U.S.A.
Attention: Robert A. Clarke track_1_comments@uspto.gov

Re: Comments on Proposed Changes To Implement the Prioritized Examination Track (Track I) of the Enhanced Examination Timing Control Procedures

Dear Commissioner:

The Japan Pharmaceutical Manufacturers Association (JPMA) appreciates the opportunity to present its views on the proposed "Changes To Implement the Prioritized Examination Track (Track I) of the Enhanced Examination Timing Control Procedures", published in the Federal Register on February 4, 2011.

1. JPMA highly appreciates the proposed changes because concern about different treatment on patent applications that are based on a prior foreign-filed application proposed in the original proposal was removed.
2. Nevertheless JPMA would make some comments on the proposed changes:
 - (a) In the proposal an applicant can request prioritized examination at the time of filing. But, JPMA hopes that the request should not be limited to time of filing, but should be allowed at anytime.
 - (b) JPMA hopes that a final action on an application the prioritized examination for which is requested should be made within a couple of months instead of twelve months.

In Japan a first action will be made within a month and a final action will be made around two months on an application the prioritized examination for which is requested.

JPMA would appreciate it if you would make an appropriate system to enhance the examination.

Very truly yours,

Yuji Watanabe
Head of Intellectual Property Committee
The Japan Pharmaceutical Manufacturers Association
e-mail: international@jpma.or.jp

About Us:

The Japan Pharmaceutical Manufacturers Association (JPMA) is a voluntary association comprising 67 research-oriented pharmaceutical companies (as of February 1, 2011).

As a member of the IFPMA (International Federation of Pharmaceutical Manufacturers & Associations), JPMA is engaged with various global issues in the pharmaceutical and healthcare sector, including countermeasures against emerging diseases across the globe and infectious diseases in developing countries, drug access problems, intellectual property rights and the threat of counterfeit drugs.

Working collaboratively with PhRMA (Pharmaceutical Research and Manufacturers of America) and EFPIA (European Federation of Pharmaceutical Industries and Associations), JPMA takes active roles at ICH (International Conference on Harmonization), which aims at international harmonization of pharmaceutical regulations.

Through mutual information sharing and close collaboration with each member organization, JPMA continues to act globally for the advancement of medical treatments for patients worldwide.